Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BCDA 
Biocardia Inc (BCDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: BCDA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.69% | Avg. Invested days 18 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/02/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.36M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.84 | 52 Weeks Range 1.62 - 4.66 | Updated Date 07/2/2025 |
52 Weeks Range 1.62 - 4.66 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.14 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -281733.35% |
Management Effectiveness
Return on Assets (TTM) -218.06% | Return on Equity (TTM) -737.89% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10463895 | Price to Sales(TTM) 3451.93 |
Enterprise Value 10463895 | Price to Sales(TTM) 3451.93 | ||
Enterprise Value to Revenue 3487.97 | Enterprise Value to EBITDA -3.16 | Shares Outstanding 5177890 | Shares Floating 3886990 |
Shares Outstanding 5177890 | Shares Floating 3886990 | ||
Percent Insiders 21.66 | Percent Institutions 4.75 |
Upturn AI SWOT
Biocardia Inc
Company Overview
History and Background
BioCardia, Inc. was founded in 1998 and is focused on developing novel therapeutics for cardiovascular diseases. It has evolved from research into clinical-stage development, focusing on cell-based therapies.
Core Business Areas
- CardiAMP Cell Therapy System: BioCardia's lead program, CardiAMP, uses a patient's own bone marrow cells to treat heart failure and chronic myocardial ischemia. It involves a diagnostic test to identify patients likely to respond to the therapy.
- AVANCE Clinical Trial: The AVANCE trial is evaluating the efficacy of CardiAMP cell therapy in patients with ischemic heart failure.
Leadership and Structure
The leadership team includes Peter Altman (President & CEO). The organizational structure is typical for a publicly traded biotech company, with departments focused on research, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- CardiAMP Cell Therapy System: This is BioCardia's primary product under development. It is a cell-based therapy for heart disease, utilizing a patient's own cells to regenerate heart tissue. Currently in clinical trials (AVANCE). Market share is pending FDA approval. Competitors include companies developing similar regenerative therapies, though direct competitors with the exact CardiAMP approach are not widely specified.
Market Dynamics
Industry Overview
The regenerative medicine industry is growing, with increasing investment in cell-based therapies for various diseases. Cardiovascular disease remains a significant global health challenge, creating a substantial market opportunity.
Positioning
BioCardia is positioned as a clinical-stage company focused on cell therapies for heart disease. Its competitive advantage lies in its proprietary CardiAMP system and diagnostic approach.
Total Addressable Market (TAM)
The TAM for heart failure therapies is estimated to be in the billions of dollars annually. BioCardia is targeting a segment of this market with its personalized cell therapy approach.
Upturn SWOT Analysis
Strengths
- Proprietary CardiAMP technology
- Personalized cell therapy approach
- Clinical-stage development
- Focus on unmet medical needs in cardiovascular disease
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Limited commercial revenue
- Susceptibility to regulatory hurdles
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- FDA approval and commercial launch
Threats
- Clinical trial failures
- Regulatory delays
- Competition from alternative therapies
- Market adoption challenges
Competitors and Market Share
Key Competitors
- MESO
- ATHX
- CRBP
Competitive Landscape
BioCardia faces competition from other companies developing cell and gene therapies for cardiovascular disease. Its competitive advantage lies in its personalized approach and specific technology platform.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress through clinical trials and research activities.
Future Projections: Future growth is contingent upon successful clinical trial outcomes and FDA approval. Analyst estimates would vary depending on these factors.
Recent Initiatives: Recent strategic initiatives include advancing the CardiAMP program through clinical trials and seeking partnerships for commercialization.
Summary
BioCardia is a clinical-stage biotech company focused on cell therapies for heart disease. Its success hinges on positive clinical trial outcomes and regulatory approval of its CardiAMP system. The company faces challenges related to funding and competition, but holds potential for growth if its therapies prove effective. Investors should be aware of the high-risk, high-reward nature of investing in a clinical-stage biotech company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimates are approximations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biocardia Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2008-03-14 | CEO, President & Director Dr. Peter A. Altman Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 17 | Website https://www.biocardia.com |
Full time employees 17 | Website https://www.biocardia.com | ||
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.